Posted by Michael Wonder on 21 May 2020
CADTH posts final recommendation for Entyvio
21 May 2020 - CADTH has completed its consideration of subcutaneous vedolizumab for the treatment of adult patients with moderately to severely active ulcerative colitis.
The CADTH Canadian Drug Expert Committee has recommended that vedolizumab subcutaneous be reimbursed for the treatment of adult patients with moderately to severely active ulcerative colitis who have had an inadequate response, loss of response, or were intolerant to either conventional therapy or infliximab, a tumour necrosis factor alpha antagonist, only if three conditions are met.
